Hartmut Juhl, MD
Tissue as diagnostic tool

Hartmut Juhl, MD, is CEO of Indivumed GmbH and its subsidiary Indivumed Inc. and Inostics GmbH. Born in Hamburg, Germany, he attended Medical School at Hamburg University and received his MD in 1986. Juhl trained in General Surgery and worked as a surgical oncologist at the Department of Surgery of the Christian-Albrechts University Hospital in Kiel from 1992 until 1998. From 1992 to 1998 he was also Head of the Cancer Research Unit at the Department of Surgery at the Hospital. His research focused on detection of minimal residual disease by immunohistochemical and PCR–approaches as well as antibody-directed therapy of GI-tract cancer.

In 1996 he received his “Habilitation” (PhD–equivalent) and became Assistant Professor at Christian–Albrechts–University in Kiel. In 1998 he ended his surgical duties to become a full-time scientist and Associate Professor at the Lombardi Comprehensive Cancer Center at Georgetown University in Washington DC. With 15 years of experience in surgery and research he became extremely familiar with all aspects, practical problems and scientific needs of biobanking and collection of tissue for diagnostic purposes.

In 2002, he founded Indivumed, GmbH in Hamburg, Germany – a company focused on promotion and development of individualized cancer therapies based on a unique clinical database and tissue collection from cancer patients. Indivumed has a subsidiary, Indivumed Inc., in the Washington DC area which is also focused on tissue and data collection. A second subsidiary of Indivumed, Inostics GmbH, was founded in 2009 with Bert Vogelstein and colleagues from Johns Hopkins University to improve DNA analysis as a basis for predicting drug response and individualizing cancer medicine. Juhl has appointments as Adjunct Professor at Georgetown University in Washington DC and the University of Hamburg in Germany.

« Previous Speaker | Next Speaker »